ЛЕКАРСТВЕННО-ИНДУЦИРОВАННАЯ ГИПЕРПРОЛАКТИНЕМИЯ В ПРАКТИКЕ ИНТЕРНИСТА
Аннотация
Гиперпролактинемия (ГПРЛ) – один из часто встречающихся нейроэндокринных синдромов, который может быть как проявлением самостоятельного заболевания (опухоли гипофиза), так и синдромом, сопровождающим ряд других болезней гипоталамо гипофизарной зоны, эндокринных заболеваний, патологии внутренних органов, поражений центральной нервной системы, а также может иметь ятрогенный характер (лекарственно-индуцированная ГПРЛ). ГПРЛ чаще встречается у женщин, но может быть и у мужчин с разными нарушениями со стороны репродукции и сексуального здоровья. Многие препараты могут стать причиной ГПРЛ. Для того, чтобы установить частоту встречаемости этой проблемы в практике интерниста, был проведен анализ литературы. Рассматривались статьи, касающиеся ГПРЛ, индуцированной конкретными типами лекарственных препаратов. В данном обзоре представлены современные взгляды отечественных и зарубежных авторов на причины и механизмы развития ГПРЛ.
Литература
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. https://doi.org/10.1210/jc.2010-1692.
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-631. https://doi.org/10.1152/physrev.2000.80.4.1523.
Giljazutdinov IA, Giljazutdinova ZSh. Nejroendokrinnaja patologija v ginekologii i akusherstvje. Moskva: MEDpress-inform; 2008. 432 p. (Russian).
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189-225. https://doi.org/10.1152/physrev.1998.78.1.189.
Bouilly J, Sonigo C, Auffret J, Gibori G, Binart N. Prolactin signaling mechanisms in ovary. Mol Cell Endocrinol. 2012;356(1-2):80-7. https://doi.org/10.1016/j.mce.2011.05.004.
Shepelkevich AP, Mantachik MV, Dydyshko YV, Shyshko EI. Hyperprolactinemic syndrome: modern approaches of diagnosis and treatment. Lechebnoje delo: nauchno-prakticheskij terapevticheskij zhurnal. 2018;(4):56-59. (Russian).
Marova EI, Dzeranova LK, Vaks VV, compilers. Giperprolaktinemija u zhenshсhin i muzhchin [Internet]. Melnichenko GA, editor. Moskva; 2007. Available from: https://clck.ru/34SKQA. (Russian).
Kalinchenko SJu. Shag vpered v lechenii giperprolaktinemii: izbrannyje lekcii. Moskva: Prakticheskaja medicina; 2010. 96 p. (Russian).
Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, Berrino F, Hallmans G, Idahl A, Krogh V, Lukanova A, Marrangoni A, Muti P, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control. 2013;24(4):741-8. https://doi.org/10.1007/s10552-013-0156-6.
Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Research. 2004;64(18):6814-6819. https://doi.org/10.1158/0008-5472.CAN-04-1870.
Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, Surico N, Vacca G. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology. 2007;148(8):4080 90. https://doi.org/10.1210/en.2006-1577.
Leaños-Miranda A, Márquez-Acosta J, Cárdenas-Mondragón GM, Chinolla-Arellano ZL, Rivera-Leaños R, Bermejo-Huerta S, Romero-Arauz JF, Alvarez-Jiménez G, Ramos-León JC, Ulloa-Aguirre A. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab. 2008;93(7):2492-9. https://doi.org/10.1210/jc.2008-0305.
Zhang L, Curhan GC, Forman JP. Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens. 2010;28(7):1400-5. https://doi.org/10.1097/HJH.0b013e328339f254.
Imrich R. The role of neuroendocrine system in the pathogenesis of rheumatic diseases (minireview). Endocr Regul. 2002;36(2):95-106.
Ignacak A, Kasztelnik M, Sliwa T, Korbut RA, Rajda K, Guzik TJ. Prolactin--not only lactotrophin. A “new” view of the “old” hormone. J Physiol Pharmacol. 2012;63(5):435-43.
Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516-524. https://doi.org/10.1001/jama.2016.19699.
Ametov AS, Pashkova EYu. Clinical cases: hyperprolactinemia in men and women of different age. Whom, how and how long to treat? Endocrinology. News. Opinions. Training. 2021;10(1):34-40. https://doi.org/10.33029/2304-95292021-10-1-34-40. https://elibrary.ru/lgexuz. (Russian).
Adamyan LV, Yarmolinskaya MI, Suslova EV. Hyperprolactinemia syndrome: from theory to practice. Reproduction problems. 2020;26(2):27-33. https://doi.org/10.17116/repro20202602127. https://elibrary.ru/ocfosp. (Russian).
Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. 2001;30(3):585-610. https://doi.org/10.1016/s0889-8529(05)70203-6.
Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ. 2002;324(7332):250-2. https://doi.org/10.1136/bmj.324.7332.250.
Dedov II, Melnichenko GA, Romancova TI, Rozhinskaja LJa, Dzeranova LK, Ilovajskaja IA, Dalantaeva NS, Barmina II. Giperprolaktinemija. Sovremennyje podhody i staryje problemy. Bulletin of reproductive health. 2009 (2):2-8. edn: RBNRLP. (Russian).
Knegtering R, Castelein S, Bous H, Linde JVDer, Bruggeman R, Kluiter H, Robert J, Bosch VD. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24:56-61. https://doi.org/10.1097/01.jcp.0000106220.36344.04.
Gorobec LN. Diagnostika, korrekcija i profilaktika nejroendokrinnyh disfunkcij u bolnyh shizofrenijej v uslovijah sovremennoj antipsihoticheskoj farmakoterapii. In: Mosolov SN, editor. Biologicheskije metody terapii psihicheskih rasstrojstv (dokazatelnaja medicina v klinicheskoj praktike). Moskva: Socialno-politicheskaja mysl; 2012. p. 830-862. (Russian).
Burchinskij SG. Problema bezopasnosti v strategii farmakoterapii atipichnymi nejroleptikami. NejroNews: psihonevrologija i nejropsihiatrija [Internet]. 2010;5(24). Available from: https://goo.su/NEia. (Russian).
Ivanov MV, Chomskij AN. Novyje podhody k korrekcii i profilaktike nejroendokrinnyh narushenij u psihicheski bolnyh v processe antipsihoticheskoj terapii. Sankt- Peterburg: SPb NIPNI im. V.M. Behtereva; 2012. 20 p. (Russian).
Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57-61. https://doi.org/10.4088/jcp.v65n0109.
Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133-5. https://doi.org/10.1176/appi.ajp.159.1.133.
Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974-7. https://doi.org/10.1001/archpsyc.60.10.974.
Jashсhinskij LB. Kasich IN, Starygina VV. Osobennosti lekarstvenno-inducirovannoj giperprolaktinemii. Molodoj uchenyj. 2016;(26-2):54-61. edn: XEODGT. (Russian).
Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther. 2003;306(2):581-7. https://doi.org/10.1124/jpet.103.050682.
Gluskin LE, Strasberg B, Shah JH. Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med. 1981;95(1):66-7. https://doi.org/10.7326/0003-4819-95-1-66.
